Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.

Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

Abstract: Conditions necessary for antibodies to human PD-1 to have agonist activity are searched and an optimized agonist antibody is provided based on the conditions and used as a therapeutic for human inflammatory diseases. An agonist antibody to human PD-1 or a functional fragment thereof, wherein the antibody or a functional fragment thereof binds to domain #7 of human PD-1 as shown in SEQ ID NO: 9 is provided.

Abstract: Provided is a method for further improving therapeutic effect and cost efficiency by ascertaining cancer type and treatment responsiveness for individual patients. The invention provides a method which includes providing information regarding cancer type of a subject, comprising assessing the cancer type of the subject using a marker relating to the amount of a D-amino acid in blood of the subject, and providing information relating to the cancer type of the subject, based on the assessment results, as well as a system for providing information pertaining to cancer in a subject, which carries out the method.

Abstract: The purpose of the present invention is to provide an antisense oligonucleotide that targets an ARL4C molecule and exerts an antitumor effect in vivo, and a nucleic acid drug using the antisense oligonucleotide. An antisense oligonucleotide that has a base sequence consisting of at least 10 consecutive bases contained in the base sequence represented by SEQ ID NO: 1. This antisense oligonucleotide targets an ARL4C molecule and thus can inhibit the expression of ARL4C in a tumor cell in vitro and suppress the migration and proliferation thereof. When systemically administered, moreover, the antisense oligonucleotide can exert an excellent antitumor effect in vivo too.

Abstract: Provided herein is a method for modulating the amount of virus in a subject comprising administering to the subject an agent for controlling an indicator associated with a D-amino acid in the subject.

Abstract: Provided herein is a method for providing information about virus infection and/or virus infection disease in a subject, comprising: making a determination on the detection and/or stage classification of virus infection and/or virus infection disease in the subject using an indicator associated with a D-amino acid in the subject; and providing information about virus infection and/or virus infection disease in the subject based on the results of the determination.

Abstract: The present invention relates to an optic nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or an anti-LRP1 antibody fragment.

Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.

Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

Abstract: The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.

Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.

Abstract: A prophylactic or therapeutic agent for an aneurysm comprising a miR-33b inhibiting substance, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.

Abstract: The present invention provides a method comprising a step of estimating the kidney function of an arbitrary subject by a regression analysis which employs the amount of a D, L-amino acid in a biological sample from the arbitrary subject as an explanatory variable and employs the amount of filtrated glomeruli in the arbitrary subject as an object variable, by employing a previously determined formula (I): Y=a1·X1+a2·X2+ . . . +an·Xn+b (I) [wherein a1 to an independently represent a constant obtained by the regression analysis; X1 to Xn independently represent a variable of the amount of the D,L-amino acid which is selected by the regression analysis; and b represents a constant obtained by the regression analysis] on the basis of the Y value calculated from the amount of the D, L-amino acid in the biological sample from the object to be evaluated. Also provided is a system for carrying out the method.

Abstract: The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.

Abstract: Finding a protein of a minute amount present on a cell membrane to provide a method for producing an antibody against the protein. Producing an antibody using a protein identified by an identification method including: a labeling step of using a labeling agent comprising at least one selected from bis-iminobiotin compounds and bis-biotin compounds to obtain cells having a labeled protein; a degradation step of preparing a degradation product for an immobilization treatment, the degradation product containing the labeled protein; an immobilization step of immobilizing the labeled protein contained in the degradation product for an immobilization treatment on a stationary phase via a streptavidin mutant; a cleavage step of releasing an analysis sample from the stationary phase on which the labeled protein is immobilized; and an analysis step of analyzing the analysis sample to identify the labeled protein.

Abstract: A nucleic acid medicine using an antisense nucleic acid to inhibit the expression of SYT13, which has better efficacy than siRNA for targeting peritoneal dissemination of gastric cancer is provided. An antisense oligonucleotide which consists of a nucleotide sequence substantially complementary to the nucleotide sequence of a specific region in human SYT13 mRNA and which can inhibit the expression of human SYT13 mRNA; and a pharmaceutical composition comprising the antisense oligonucleotide are also provided.

Abstract: The present invention provides a method for assisting in the evaluation of the condition of kidneys, a system for evaluating the condition of kidneys, and a program for evaluating the condition of kidneys, using, as an index, the ratio of reabsorption of D-serine and/or D-asparagine in target kidneys and excretion of the D-serine and/or D-asparagine. The present invention also provides a method for monitoring the condition of kidneys and a method for monitoring the effect of treatment on kidney disease.

Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.

Abstract: The present invention provides: a method for assisting the evaluation of renal pathological conditions, said method comprising using, as an index, a combination of renal reabsorption and excretion ratios of D-serine and/or D-asparagine in a subject with the blood D-serine and/or D-asparagine levels; a system for evaluating renal pathological conditions; and a program for evaluating renal pathological conditions. The present invention also provides: a method for monitoring renal pathological conditions; and a method for monitoring an effect of treating a renal disease.